To include your compound in the COVID-19 Resource Center, submit it here.

China approves Hengrui breast cancer drug on Phase II data

By Jaime De Leon | Aug 31, 2018 | 6:42 PM GMT

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China’s State Drug Administration conditionally approved pyrotinib (SHR-1258, HTI-1001) in combination with capecitabine to treat HER2-positive, advanced or metastatic breast

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE